IQVIA_Rules_Based_Medicine_Logo - rgb

(+01) 512 835 8026

Email us

Type your search term and press "enter."

Interleukin-13

Interleukin-13

Interleukin-13 (IL-13) is a 13kD protein secreted primarily by T helper type 2 (Th2) cells and natural killer cells, mast cells, basophils, and eosinophils. IL-13 plays a central role in the Th2 response and shares many biological activities with IL-4, as they share a common receptor subunit (a subunit). IL-13 receptors (IL-4Ra and two IL-13 binding proteins, IL-13Ra1 and IL-13Ra2) are expressed on human B cells, basophils, eosinophils, mast cells, endothelial cells, fibroblasts, monocytes, macrophages, respiratory epithelial cells, and smooth muscle cells. The primary functions of IL-13 is to regulate inflammation, mucus production, tissue remodeling, and fibrosis. IL-13 is also essential for host protection against helminth infections. IL-13 is an important therapeutic target for several diseases, including asthma, fibrosis, ulcerative colitis, and other inflammatory diseases in which IL-13 is overproduced. Overproduction of IL-13 drives airway inflammation and bronchial obstruction, a pathogenesis of asthma. IL-13 driven eosinophilic disorder plays a role in atopic dermatitis, eosinophilic esophagitis, and other chronic inflammatory intestinal diseases. IPF patients have elevated levels of IL-13 in the bronchoalveolar lavage fluid, and those with rapid progressive disease have enhanced pathway activation of IL-13. Anti-IL-13 therapy (tralokinumab, lebrikizumab) is being actively investigated in asthma, allergic inflammatory diseases, and IPF.

Swiss-Prot Accession Number: P35225


Bibliography

Seladelpar treatment reduces interleukin-31 and pruritus in patients with primary biliary cholangitis (2023) Andreas E. Kremer, Marlyn J. Mayo, Gideon M. Hirschfield, Cynthia Levy, Christopher L. Bowlus, David E. Jones, Jeff D. Johnson, Charles A. McWherter, Yun-Jung Choi Hepatology

medical_services Therapy Indications

Antitumor necrosis factor-like ligand 1A therapy targets tissue inflammation and fibrosis pathways and reduces gut pathobionts in ulcerative colitis (2021) Hassan-Zahraee M, Ye Z, Baniecki ML, Li X, Hyde CL, Zhang J, Raha N, Karlsson F, Quan J, Ziemek D, Neelakantan S, Lepsy C, Allegretti JR, Romatowski J, Scherl EJ, Klopocka M, Danese S, Chandra DE, Schoenbeck U, Vincent MS, Longman R,Hung KE Inflammatory Bowl Diseases

medical_services Therapy Indications

Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC, a recombinant mycobacterium bacillus calmette guerin (BCG), in patients with non-muscle invasive bladder cancer and previous failure of conventional BCG therapy (2020) Rentsch CA, Bosshard P, Mayor G, Rieken M, Puschel H, Wirth G, Cathomas R, Parzmair GP, Grode L, Eisele B, Sharma H, Gupta M, Gairola S, Shaligram U, Goldenberger D, Spertini F, Audran R, Enoui M, Beradi S, Hayoz S, Wicki A Oncoimmunology

medical_services Therapy Indications

Assessment of Proteomic Measures Across Serious Psychiatric Illness. (2017) Schulz SC, Overgaard S, Bond DJ, Kaldate R. Clin Schizophr Relat Psychoses

medical_services Therapy Indications

Critical proinflammatory role of thymic stromal lymphopoietin and its receptor in experimental autoimmune arthritis (2011) Hartgring SA, Willis CR, Dean CE Jr, Broere F, van Eden W, Bijlsma JW, Lafeber FP, van Roon JA Arthritis Rheum. Jul;63(7):1878-87

medical_services Therapy Indications

Human plasma inflammatory response during 5 days of exercise training in the heat (2011) Hailes WS, Slivka D, Cuddy J, Ruby BC Journal of Thermal Biology

medical_services Therapy Indications